# US 2016/0355455 A1 · Compounds and methods for delivery of prostacyclin analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355455 A1
- Document ID: US20160355455A1
- Status: Published application
- Kind: A1
- Application number: 15/239,014
- Filed: 2016-08-17
- Published: 2016-12-08
- Earliest claimed: 2003-05-22
- Assignees: United Therapeutics Corporation
- Applicants: United Therapeutics Corporation
- Inventors: Ken Phares; David Mottola
- Web page: https://patentgrep.com/patent/US20160355455A1

## CPC

- C07C 59/13: containing rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/223: of alpha-aminoacids
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 51/412: {by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part}
- C07C 59/70: Ethers of hydroxy-acetic acid {, e.g. substitutes on the ring}
- C07C 69/712: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C07C 229/08: the nitrogen atom of the amino group being further bound to hydrogen atoms
- C07C 235/06: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 235/08: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C 259/06: having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C07F 9/091: {with hydroxyalkyl compounds with further substituents on alkyl}
- C07F 9/117: with cycloaliphatic alcohols
- C07C 2603/10: containing five-membered rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

## Claims

### Claim 1

A compound having structure I:
wherein R1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR1 are substituted or unsubstituted glycolamide esters, and
wherein R2 and R3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR2 and OR3 form esters of amino acids, with the proviso that all of R1, R2, and R3 are not H;
an enantiomer of the compound; or
a pharmaceutically acceptable salt of the compound.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is H.

### Claim 3 (depends on 2)

The compound of claim 2, wherein at least one of R2 and R3 is phosphate.

### Claim 4 (depends on 3)

The compound of claim 3, wherein each of R2 and R3 is phosphate.

### Claim 5 (depends on 3)

The compound of claim 3, wherein R2 is H and R3 is phosphate.

### Claim 6 (depends on 3)

The compound of claim 3, wherein R2 is phosphate and R3 is H.

### Claim 7 (depends on 2)

The compound of claim 2, wherein at least one of OR2 and OR3 forms an ester of an amino acid.

### Claim 8 (depends on 7)

The compound of claim 7, wherein OR2 forms an ester of an amino acid and R3 is H.

### Claim 9 (depends on 7)

The compound of claim 7, wherein R2 is H and OR3 forms an ester of an amino acid.

### Claim 10

A pharmaceutical composition comprising:
(A) a compound having structure I:
wherein R1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR1 are substituted or unsubstituted glycolamide esters, and
wherein R2 and R3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR2 and OR3 form esters of amino acids, with the proviso that all of R1, R2, and R3 are not H;
an enantiomer of the compound; or
a pharmaceutically acceptable salt of the compound; and
(B) a pharmaceutically acceptable excipient.

### Claim 11 (depends on 10)

The composition of claim 10, wherein R1 is H.

### Claim 12 (depends on 11)

The composition of claim 11, wherein at least one of R2 and R3 is phosphate.

### Claim 13 (depends on 12)

The composition of claim 12, wherein each of R2 and R3 is phosphate.

### Claim 14 (depends on 12)

The composition of claim 12, wherein R2 is H and R3 is phosphate.

### Claim 15 (depends on 12)

The composition of claim 12, wherein R2 is phosphate and R3 is H.

### Claim 16 (depends on 11)

The composition of claim 11, wherein at least one of OR2 and OR3 forms an ester of an amino acid.

### Claim 17 (depends on 16)

The compound of claim 16, wherein OR2 forms an ester of an amino acid and R3 is H.

### Claim 18 (depends on 16)

The compound of claim 16, wherein R2 is H and OR3 forms an ester of an amino acid.

### Claim 19

A method of treating pulmonary hypertension in a human subject comprising administering to a subject in need thereof an effective amount of a compound having structure I:
wherein R1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR1 are substituted or unsubstituted glycolamide esters, and
wherein R2 and R3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR2 and OR3 form esters of amino acids, with the proviso that all of R1, R2 and R3 are not H;
an enantiomer of the compound; or
a pharmaceutically acceptable salt of the compound.

### Claim 20 (depends on 19)

The method of claim 19, wherein R1 is H.

### Claim 21 (depends on 20)

The method of claim 20, wherein at least one of R2 and R3 is phosphate.

### Claim 22 (depends on 21)

The method of claim 21, wherein each of R2 and R3 is phosphate.

### Claim 23 (depends on 21)

The method of claim 21, wherein R2 is H and R3 is phosphate.

### Claim 24 (depends on 21)

The method of claim 21, wherein R2 is phosphate and R3 is H.

### Claim 25 (depends on 20)

The method of claim 20, wherein at least one of OR2 and OR3 forms an ester of an amino acid.

### Claim 26 (depends on 25)

The method of claim 25, wherein OR2 forms an ester of an amino acid and R3 is H.

### Claim 27 (depends on 25)

The method of claim 25, wherein R2 is H and OR3 forms an ester of an amino acid.

### Claim 28 (depends on 19)

The method of claim 19, wherein said administering is performed orally.

### Claim 29 (depends on 19)

The method of claim 19, wherein said administering is performed subcutaneously.
